Novel Metabolic Activator & Exercise Mimetic Compound
Dragon Pharma SLU-PP-332 500 mcg represents the cutting edge of metabolic pharmacology, offering a groundbreaking "exercise mimetic" approach to body composition and performance. This innovative compound, developed from university research, is designed to activate the same biological pathways that are naturally stimulated by prolonged aerobic exercise. Unlike traditional stimulant-based fat burners, SLU-PP-332 works by targeting estrogen-related receptors (ERRα, ERRβ, and ERRγ), which are master regulators of energy metabolism in muscles, the heart, and the brain. By pharmacologically "telling" your skeletal muscle to behave as if it's endurance-trained, this compound can shift your entire body's metabolism towards increased fat burning and energy expenditure, even at rest.
Produced under strict cGMP standards in Dragon Pharma's European facilities, each 500 mcg tablet delivers a precise dose of this potent research compound. Pre-clinical studies published in peer-reviewed journals have demonstrated remarkable effects: treated subjects exhibited significantly increased whole-body fatty acid oxidation, reduced fat mass accumulation, and dramatically improved exercise endurance—in some cases by up to 70%. For the athlete or bodybuilder, this translates to a powerful tool for cutting phases. It promotes efficient fat loss by converting the body into a fat-burning furnace, while its muscle-preserving and endurance-boosting properties help you maintain training intensity and lean mass in a calorie deficit.
It is crucial to understand that SLU-PP-332 is a potent research chemical with a novel mechanism. While early data shows a promising safety profile with no severe side effects reported in animal models, and it is not hepatotoxic or linked to water retention or blood pressure issues, its long-term effects in humans are not yet fully characterized. Therefore, it is intended for informed research use by experienced individuals. Its non-stimulant, non-suppressive nature makes it a compelling alternative for those seeking results beyond conventional fat-loss agents.
Key Benefits:
Each sachet contains 100 tablets of 500mcg SLU-PP-332, manufactured under strict quality control standards in Dragon Pharma's certified facilities.
| Product Name | SLU-PP-332 500 mcg |
| Manufacturer | Dragon Pharma |
| Substance | SLU-PP-332 |
| Packaging | 100 tablets in sealed sachet |
| Lab Test Result | 534.91 mcg (Oct 2025) - Exceeds label claim |
| Half-Life | Approximately 6 - 8 hours |
| Recommended Cycle | 4 - 8 weeks |
| Form | Oral tablet |
| Aromatization | No |
| Dosage (Research) | 500 - 1000 mcg per day (split into 2 doses) |
Important Note: SLU-PP-332 is an experimental research compound. The following guidelines are based on current non-clinical data and anecdotal reports. Start with the lowest dose to assess individual tolerance.
SLU-PP-332 does NOT require a traditional PCT. It does not suppress the hypothalamic-pituitary-testicular axis (HPTA) or natural testosterone production. Its mechanism is purely metabolic, targeting ERR receptors rather than the endocrine system. Therefore, you can conclude your cycle without the need for SERMs like Clomid or Nolvadex. A gradual taper is not necessary but ceasing use is sufficient.
While not hepatotoxic, supporting overall metabolic health is prudent. Ensure adequate hydration and a diet rich in micronutrients to support increased metabolic turnover. Some anecdotal reports mention transient fatigue, so listen to your body and ensure sufficient rest. For cardiovascular health in any cutting phase, consider support supplements like Omega-3s or CoQ10. As with any compound that alters metabolism, maintaining a balanced diet with sufficient protein is crucial to leverage its muscle-preserving potential.
Note: The independent third-party lab test dated October 16, 2025, confirms a potency of 534.91 mcg per tablet, exceeding the labeled 500 mcg claim. This demonstrates Dragon Pharma's commitment to consistent overdosing, ensuring you receive a product of verified and superior potency.
To preserve the integrity of this advanced compound, proper storage is essential.
SLU-PP-332 is an experimental metabolic compound known as an 'exercise mimetic.' It is studied for its potential to provide benefits similar to endurance training, such as enhancing fat loss by increasing energy expenditure and fatty acid oxidation, boosting exercise endurance, and improving metabolic health. It works by activating estrogen-related receptors (ERRs) in energy-demanding tissues like muscle, effectively reprogramming metabolism without requiring increased physical activity.
Current data from pre-clinical research indicates minimal severe side effects. However, due to its potent metabolic effects, some users may experience transient fatigue. It is not hepatotoxic, does not cause water retention or acne, and is unlikely to raise blood pressure. As an experimental research compound, its long-term safety profile in humans is not yet established. Responsible, low-dose use is recommended to assess individual tolerance.
Dragon Pharma's SLU-PP-332 comes in convenient 500 mcg oral tablets. Based on current experimental protocols, a common daily dosage ranges from 500 mcg to 1000 mcg. Due to its active half-life of approximately 6–8 hours, the total daily dose is typically split into two administrations (e.g., morning and afternoon). It's crucial to start at the lower end of this range (500 mcg/day) to assess individual tolerance before considering any increase. A typical research cycle lasts 4 to 8 weeks.
No, Post Cycle Therapy (PCT) is not required with SLU-PP-332. Unlike anabolic steroids or certain SARMs, SLU-PP-332 does not suppress the body's natural testosterone production or affect the hypothalamic-pituitary-gonadal (HPG) axis. Its mechanism targets metabolic pathways (ERR receptors) related to energy expenditure and fat oxidation, not the endocrine system. Therefore, you can conclude a cycle without the need for SERMs like Clomid or Nolvadex.
SLU-PP-332 represents a novel, non-stimulant approach. Unlike beta-2 agonists like Clenbuterol, which are stimulants that raise heart rate, or appetite suppressants like Sibutramine, SLU-PP-332 works by mimicking the cellular effects of aerobic exercise. It shifts the body's metabolism to use fat as its primary fuel source, potentially increasing endurance and preserving muscle during a calorie deficit. This makes it a unique tool for body recomposition with a different side effect profile.